Detection of genotoxic substances in cancer patients receiving antineoplastic drugs

• Published in: Annals of the New York Academy of Sciences Vol. 534; p. 776
• Main Authors: Kohn, A, Donchin, M, Jacobs, J Y, Horn, Y, Gibor, Y, Fish, F, Riesenfeld, G, Kirenberg, F, Lampert, I, Halachmi, A
• Format: Journal Article
• Language: English
• Published: United States 1988
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - urine; Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics; Antineoplastic Combined Chemotherapy Protocols - urine; Cisplatin - administration & dosage; Cisplatin - urine; Cyclophosphamide - administration & dosage; Cyclophosphamide - urine; Doxorubicin - administration & dosage; Doxorubicin - urine; Female; Humans; Mutagenicity Tests; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - urine; Vincristine - administration & dosage; Vincristine - urine
• ISSN: 0077-8923
• DOI: 10.1111/j.1749-6632.1988.tb30166.x

A short-term bacterial mutation test, the SOS Chromotest, has been used to detect the excretion in urine of genotoxic metabolites of antineoplastic drugs administered to cancer patients. In this test, the damage to the DNA of the test bacteria is expressed by the production of beta-galactosidase, which can be quantitatively assessed and is proportional to the concentration of the drug. Kinetic curves of excretion for adriamycin, bleomycin, dacarbazine, cis-platinum and vincristine and their mixtures have been constructed from standard curves relating the intensity of the beta-galactosidase response to the concentration of drugs dissolved in normal urine. Comparative data on extraction and concentration of the drugs from urine or serum by means of selective resin or silica columns are presented.